Parkinsonism & Related Disorders
Volume 13, Issue 3 , Pages 165-169 , April 2007

Calcium channel blockers and β-blockers in relation to Parkinson's disease

  • Thanh G.N. Ton

      Affiliations

    • Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195-7326, USA
    • Corresponding Author InformationCorresponding author. Tel.: +12066161109; fax: +12066853990.
    • ,
  • Susan R. Heckbert

      Affiliations

    • Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195-7326, USA
    • ,
  • W.T. Longstreth Jr.

      Affiliations

    • Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195-7326, USA
    • Department of Neurology, University of Washington, Box 359775, Seattle, WA 98195-9775, USA
    • ,
  • Mary Anne Rossing

      Affiliations

    • Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195-7326, USA
    • Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1101 Fairview Ave N., PO Box 19024, Seattle, WA 98109, USA
    • ,
  • Walter A. Kukull

      Affiliations

    • Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195-7326, USA
    • ,
  • Gary M. Franklin

      Affiliations

    • Department of Neurology, University of Washington, Box 359775, Seattle, WA 98195-9775, USA
    • Department of Environmental and Occupational Health Sciences, University of Washington, Box 357234, Seattle, WA 98195-7234, USA
    • ,
  • Phillip D. Swanson

      Affiliations

    • Department of Neurology, University of Washington, Box 359775, Seattle, WA 98195-9775, USA
    • ,
  • Terri Smith-Weller

      Affiliations

    • Department of Environmental and Occupational Health Sciences, University of Washington, Box 357234, Seattle, WA 98195-7234, USA
    • ,
  • Harvey Checkoway

      Affiliations

    • Department of Epidemiology, University of Washington, Box 357236, Seattle, WA 98195-7326, USA
    • Department of Environmental and Occupational Health Sciences, University of Washington, Box 357234, Seattle, WA 98195-7234, USA

Received 24 May 2006 ,Revised 18 July 2006 ,Accepted 26 August 2006.

References 

  1. Paganini-Hill A. Risk factors for parkinson's disease: the leisure world cohort study. Neuroepidemiology. 2001;20:118–124
  2. McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, et al. The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology. 1998;17:310–317
  3. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer. 1997;80:1438–1447
  4. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348:493–497
  5. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer?. Am J Hypertens. 1996;9:695–699
  6. Jick H, Madsen S, Nudelman PM, Perera DR, Stergachis A. Postmarketing follow-up at group health cooperative of puget sound. Pharmacotherapy. 1984;4:99–100
  7. Rodnitzky RL. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease?. Drugs. 1999;57:845–849
  8. Weiss JH, Pike CJ, Cotman CW. Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J Neurochem. 1994;62:372–375
  9. Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 1996;741:185–196
  10. Kupsch A, Gerlach M, Pupeter SC, Sautter J, Dirr A, Arnold G, et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport. 1995;6:621–625
  11. Daniel JR, Mauro VF. Extrapyramidal symptoms associated with calcium-channel blockers. Ann Pharmacother. 1995;29:73–75
  12. Bing G, Zhang Y, Watanabe Y, McEwen BS, Stone EA. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 1994;668:261–265
  13. Soldani P, Fornai F. The functional anatomy of noradrenergic neurons in Parkinson's disease. Funct Neurol. 1999;14:97–109
  14. Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol. 1991;30:365–374
  15. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 2002;155:732–738
  16. Wickersham RM, Novak KK, editors. Drug Facts and comparisons. St. Louis, MO: Wolters Kluwer Health; 2005.
  17. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem. 1994;63:1987–1990
  18. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord. 2006;12(3):185–189
  19. Garcia-Albea E, Jimenez-Jimenez FJ, Ayuso-Peralta L, Cabrera-Valdivia F, Vaquero A, Tejeiro J. Parkinsonism unmasked by verapamil. Clin Neuropharmacol. 1993;16:263–265
  20. Saunders KW, Stergachis A, Von Korff M. Group health cooperative of puget sound. In:  Strom B editors. Pharmacoepidemiology. West Sussex: Wiley; 1994;p. 171–185

PII: S1353-8020(06)00221-5

doi: 10.1016/j.parkreldis.2006.08.011

Parkinsonism & Related Disorders
Volume 13, Issue 3 , Pages 165-169 , April 2007

Article Tools